Security
Stevanato Group S.p.A. · STVN
STVNNYSECommon stockCurrentCIK 1849853Updated Oct 6, 2026
STVN price & chart
Loading TradingView…
NYSE:STVN on TradingView ↗About the company
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · EURSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | 139,831,000Source | 117,766,000Source | 145,690,000Source | 143,016,000Source |
| Cash flows from financing activities: | ||||
| Dividends paid | —Source | —Source | —Source | —Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | 796,000Source | -841,000Source | -1,932,000Source | 215,000Source |
| DividendsPaidClassifiedAsFinancingActivitiesEUR | 14,737,000Source | 14,457,000Source | 14,294,000Source | 13,500,000Source |
| GeneralAndAdministrativeExpenseEUR | 99,664,000Source | 93,747,000Source | 88,946,000Source | 85,747,000Source |
| GoodwillEUR | 49,983,000Source | 49,983,000Source | 49,983,000Source | 47,243,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | 59,906,000Source | 64,261,000Source | 76,765,000Source | 25,789,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | 6,960,000Source | 7,411,000Source | 3,152,000Source | 3,466,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | 1,440,000Source | 1,283,000Source | 922,000Source | 752,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 6,279,000Source | 6,476,000Source | 5,939,000Source | 6,595,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | 150,001,000Source | 190,172,000Source | 247,512,000Source | 13,207,000Source |
| ProceedsFromIssuingSharesEUR | — | 169,772,000Source | — | — |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | 1,860,000Source | 3,147,000Source | 577,000Source | 146,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 11,276,000Source | 10,971,000Source | 8,696,000Source | 8,098,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | 106,923,000Source | 155,790,000Source | 68,999,000Source | 37,648,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Total RevenueEUR | 1,186,282,000Source | 1,104,036,000Source | 1,085,354,000Source | 983,680,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.28Source | 0.28Source | 0.28Source | 0.28Source |
| BasicEarningsLossPerShareEUR/shares | 0.51Source | 0.43Source | 0.55Source | 0.54Source |
| CurrentTaxExpenseIncomeEUR | 58,369,000Source | 58,572,000Source | 62,610,000Source | 57,400,000Source |
| DeferredTaxExpenseIncomeEUR | -9,890,000Source | -15,209,000Source | -16,815,000Source | -12,990,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | 9,890,000Source | 15,209,000Source | 16,815,000Source | 12,990,000Source |
| DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossEUR | 88,565,000Source | 80,652,000Source | — | — |
| DepreciationAndAmortisationExpenseEUR | — | — | 78,480,000Source | 64,822,000Source |
| DepreciationRightofuseAssetsEUR | 6,121,000Source | 6,892,000Source | 6,247,000Source | 6,325,000Source |
| DilutedEarningsLossPerShareEUR/shares | 0.51Source | 0.43Source | 0.55Source | 0.54Source |
| EmployeeBenefitsExpenseEUR | 331,279,000Source | 309,015,000Source | 286,203,000Source | 256,373,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | — | 1,433,000Source | — |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedEUR | 1,935,000Source | 5,172,000Source | 4,749,000Source | 3,968,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | 2,033,000Source | 1,392,000Source | 2,118,000Source | 1,673,000Source |
| FinanceCostsEUR | 22,666,000Source | 23,180,000Source | 31,417,000Source | 29,840,000Source |
| FinanceIncomeEUR | 12,971,000Source | 22,326,000Source | 20,250,000Source | 25,050,000Source |
| GeneralAndAdministrativeExpenseEUR | 99,664,000Source | 93,747,000Source | 88,946,000Source | 85,747,000Source |
| GrossProfitEUR | 343,876,000Source | 302,319,000Source | 339,893,000Source | 319,801,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillEUR | 0Source | 0Source | 0Source | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillEUR | 0Source | 0Source | 0Source | 0Source |
| IncomeTaxExpenseContinuingOperationsEUR | 49,275,000Source | 42,522,000Source | 43,863,000Source | 44,625,000Source |
| InterestExpenseEUR | 5,621,000Source | 6,105,000Source | 3,734,000Source | 3,363,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | 862,000Source | 759,000Source | 581,000Source | 573,000Source |
| NetForeignExchangeLossEUR | 15,722,000Source | — | — | — |
| OtherOperatingIncomeExpenseEUR | 8,244,000Source | 9,091,000Source | 10,423,000Source | 18,850,000Source |
| ProfitLossAttributableToNoncontrollingInterestsEUR | -8,000Source | -12,000Source | 59,000Source | 167,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | 139,839,000Source | 117,778,000Source | 145,631,000Source | 142,849,000Source |
| ProfitLossBeforeTaxEUR | 189,106,000Source | 160,288,000Source | 189,553,000Source | 187,641,000Source |
| ProfitLossFromOperatingActivitiesEUR | 198,801,000Source | 161,142,000Source | 200,720,000Source | 192,431,000Source |
| ResearchAndDevelopmentExpenseEUR | 25,436,000Source | 31,668,000Source | 35,672,000Source | 34,387,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodEUR | — | — | 0Source | 0Source |
Filing attachments
stvn-ex99_1.htm · 6-K · 2026-11-03
Stevanato Group Q3 2026 Financial Results November 3, 2026 Exhibit 99.1 Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) and which involve known and unknown risks, uncertainties and assumptions because they relate to events and depend on circumstan…
Read attachment ↗stvn-ex99_1.htm · 6-K · 2026-11-03
EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) - November 3, 2026 - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2026. Third Quarter of 2026 Highlights (comparisons …
Read attachment ↗stvn-ex99_1.htm · 6-K · 2026-08-06
Exhibit 99.1 Stevanato Group S.p.A. "Half Year 2026 Financial Results Conference Call" Tuesday, August 04, 2026, 14:30 CET Moderators: Franco Stevanato, Chairman and Chief Executive Officer Marco Dal Lago, Chief Financial Officer Lisa Miles, Chief Communication Officer & Senior VP of Investor Relations Operator: Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the Stevanato Group Half Year 2…
Read attachment ↗stvn-ex99_1.htm · 6-K · 2026-08-04
Stevanato Group Q2 2026 Financial Results August 4, 2026 Exhibit 99.1 Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) and which involve known and unknown risks, uncertainties and assumptions because they relate to events and depend on circumstance…
Read attachment ↗stvn-ex99_1.htm · 6-K · 2026-08-04
EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) - August 4, 2026 - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 20…
Read attachment ↗d122142dex991.htm · 6-K · 2026-06-05
Exhibit 99.1 Press Release Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting All Resolutions Proposed to Shareholders Passed Piombino Dese, Italy, June 3rd, 2026. Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the shareholders at the …
Read attachment ↗